Immediate commercial availability for high-demand peptide raw materials optimized for metabolic, emergency care, and endocrine therapeutic formulations across Indonesia.
The pharmaceutical industry in Indonesia, centered around the Greater Jakarta area (Jabodetabek)—including strategic industrial hubs such as Cikarang, Karawang, and Tangerang—is undergoing a profound transformation. Driven by the expansion of the National Health Insurance scheme (Jaminan Kesehatan Nasional - JKN) administered by BPJS Kesehatan, the local market's demand for high-quality therapeutic drugs has escalated exponentially. Among advanced therapeutic classes, Peptide Active Pharmaceutical Ingredients (APIs) have emerged as a critical pillar for addressing non-communicable diseases (NCDs), including Type-2 diabetes, cardiovascular disorders, gastrointestinal conditions, and oncology indications.
Historically dependent on imported finished pharmaceutical forms, pharmaceutical manufacturers in Jakarta are increasingly establishing domestic primary synthesis and secondary formulation capabilities. However, due to the high barrier to entry associated with solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and complex chromatographic purification systems (RP-HPLC), foreign enterprise collaboration remains vital. Leading Jakarta-based pharmaceutical companies require trustworthy global partners capable of supplying cGMP-compliant, high-purity Peptide APIs backed by complete drug master files (DMFs) and regulatory documentation aligned with the standards of Indonesia’s National Agency of Drug and Food Control (BPOM - Badan Pengawas Obat dan Makanan).
Streamlined support for registration dossiers, stability studies (ICH Q1A-Q1E) tailored to Climatic Zone IVb (hot and humid conditions typical for Jakarta), and complete analytical validation data.
Assistance in meeting Law No. 33/2014 regarding Halal Product Assurance (BPJPH). Ensuring synthetic amino acid origins, non-animal reagents, and zero cross-contamination in peptide processing lines.
Robust thermal packing systems designed for temperatures between -20°C and 2-8°C, protecting sensitive peptide tertiary structures against tropical transit challenges in Southeast Asia.
The global peptide drug market is undergoing a revolutionary paradigm shift. Driven by breakthroughs in glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP co-agonists such as Semaglutide, Tirzepatide, and Cagrilintide, peptide manufacturing has transitioned from niche specialty production to high-tonnage industrial synthesis.
Modern peptide API manufacturing utilizes hybrid strategies to maximize yield and purity while optimizing production costs. Short-to-medium peptide fragments are synthesized via high-efficiency Solid-Phase Peptide Synthesis (SPPS) using Fmoc chemistry, followed by segment condensation in the liquid phase (LPPS). This approach effectively circumvents steric hindrance, minimizes aggregation events during chain elongation, and permits rigorous purification of individual peptide fragments prior to final assembly.
Traditional peptide synthesis requires significant solvent volumes, notably N,N-Dimethylformamide (DMF) and N-Methyl-2-pyrrolidone (NMP). Advanced manufacturing facilities are pioneering eco-friendly alternatives including 2-Methyltetrahydrofuran (2-MeTHF) and green coupling reagents. Coupled with continuous-flow microreactors, these innovations drastically reduce cycle times, minimize epimerization/racemization, and yield lower impurity profiles for complex sequences.
Peptide APIs supplied to pharmaceutical formulators in Jakarta serve vital medical requirements across multiple hospital sectors and private clinic networks in Indonesia:
Gentolex’s overarching mission is to create strategic opportunities connecting global pharmaceutical markets with dependable technical services and high-purity, cGMP-certified chemical products. Up to date, Gentolex Group has served premier pharmaceutical clients in over 10 countries, establishing international corporate hubs with strategic operations in Mexico, South Africa, and regional support spanning Southeast Asia.
Our main services focus on supplying synthetic peptide APIs, Custom Peptide Synthesis, Finished Dosage Form (FDF) License Out, Comprehensive Technical Support & Regulatory Consultation, Turnkey Product Line and Lab Setup, as well as Strategic Sourcing & Integrated Supply Chain Solutions.
Connect with Our Technical Team
An overall factory construction area of 250,000 square meters designed under strict international standards to offer flexible, highly scalable, and cost-effective synthesis solutions.
Gentolex offers an extensive range of APIs and advanced intermediates for development studies and commercial applications under cGMP standards. Complete DMF, CEP, and audit support provided.
Custom peptide sequence design, chemical modifications including lipidation, PEGylation, cyclization (disulfide bonds, head-to-tail), and non-natural amino acid incorporation.
For clients seeking to streamline supply chain complexity, we provide end-to-end procurement services supported by verified global quality assurance networks.
Explore our technical publications regarding synthetic neuropeptides, novel therapeutic molecules, and bioactive peptide bulk materials.
Explore our full line of synthetic therapeutic peptide APIs available for importation and distribution in the Jakarta commercial market and globally.
Partnering with leading global bio-pharmaceutical brands, research institutes, and regional formulators in Southeast Asia and beyond.
Addressing technical, regulatory, and logistical inquiries for pharmaceutical procurement teams in Indonesia.
Partner with a trusted global manufacturer offering high-purity Peptide APIs, robust DMF documentation, and customized supply chain solutions.
Send Inquiry Now
